- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained
MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained” on Tuesday, October 13, 2020 at 6 PM EDT.
On Tuesday, October 13, MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained” at 6 PM EDT.
The COVID-19 Coalition comprises of a group of nationally recognized experts who serve as an advisory panel with the goal to equip providers with the resources they need to enhance patient outcomes amid the coronavirus disease 2019 pandemic. Through this alliance, MJH Life Sciences™ brings together biweekly events to keep health care professionals abreast of emerging COVID-19 science and news.
The upcoming webinar event will convene a group of experts including pharmacists who serve on treatment guideline panels for both the National Institutes of Health and Infectious Diseases Society of America to discuss how the treatment landscape for COVID-19 evolves each and every day. Learn more about the current treatment agents in our arsenal, including when or in which patients to use, as well as a review of the therapeutic pipeline.
Register for the webinar here.
COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows
November 27th 2023The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.
